{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T04:12:42Z","timestamp":1746159162321,"version":"3.40.4"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["T32ES007091","R01 ES028668"],"award-info":[{"award-number":["T32ES007091","R01 ES028668"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.dmd.2025.100043","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T09:36:22Z","timestamp":1738056982000},"page":"100043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alterations of valsartan pharmacokinetics in a rodent model of metabolic dysfunction\u2013associated steatohepatitis"],"prefix":"10.1016","volume":"53","author":[{"given":"Dominique O.","family":"Farrera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina M.","family":"Alaaldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paige","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paxton A.","family":"Sample","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paige","family":"Lenzen-Hammerel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher S.","family":"LaMadrid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Haymore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0591-0017","authenticated-orcid":false,"given":"Stephen H.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan J.","family":"Cherrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmd.2025.100043_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40264-014-0239-7","article-title":"The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases","volume":"38","author":"Abraham","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.dmd.2025.100043_bib2","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3390\/ijms19030855","article-title":"Regulation of organic anion transporting polypeptides (OATP) 1B1- and OATP1B3-mediated transport: an updated review in the context of OATP-mediated drug-drug interactions","volume":"19","author":"Alam","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dmd.2025.100043_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/07853890802552437","article-title":"New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)","volume":"41","author":"Ali","year":"2009","journal-title":"Ann Med"},{"key":"10.1016\/j.dmd.2025.100043_bib3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/cpt.997","article-title":"Transporter-mediated alterations in patients with NASH increase systemic and hepatic exposure to an OATP and MRP2 substrate","volume":"104","author":"Ali","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100043_bib5","series-title":"Profiles of Drug Substances, Excipients and Related Methodology","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/bs.podrm.2015.01.004","article-title":"Valsartan","volume":"40","author":"Ardiana","year":"2015"},{"key":"10.1016\/j.dmd.2025.100043_bib6","first-page":"149","article-title":"Clinical utility of valsartan in the treatment of hypertension in children and adolescents","volume":"5","author":"Baracco","year":"2011","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.dmd.2025.100043_bib7","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1001\/jama.2021.13844","article-title":"US emergency department visits attributed to medication harms, 2017-2019","volume":"326","author":"Budnitz","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.dmd.2025.100043_bib8","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1124\/dmd.113.055996","article-title":"Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models","volume":"42","author":"Canet","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100043_bib9","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1124\/dmd.114.062703","article-title":"Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis","volume":"43","author":"Canet","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100043_bib10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1124\/jpet.113.211284","article-title":"Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression","volume":"348","author":"Clarke","year":"2014","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.dmd.2025.100043_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jhep.2014.02.021","article-title":"Synergistic interaction between genetics and disease on pravastatin disposition","volume":"61","author":"Clarke","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.dmd.2025.100043_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.drudis.2010.11.016","article-title":"Angiotensin II receptors and drug discovery in cardiovascular disease","volume":"16","author":"Dasgupta","year":"2011","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.dmd.2025.100043_bib14","article-title":"Misregulation of membrane trafficking processes in human nonalcoholic steatohepatitis","volume":"32","author":"Dzierlenga","year":"2018","journal-title":"J\u00a0Biochem Mol Toxicol"},{"key":"10.1016\/j.dmd.2025.100043_bib15","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1124\/dmd.116.071415","article-title":"Nonalcoholic steatohepatitis modulates membrane protein retrieval and insertion processes","volume":"44","author":"Dzierlenga","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100043_bib16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1124\/jpet.114.220764","article-title":"Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis","volume":"352","author":"Dzierlenga","year":"2015","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.dmd.2025.100043_bib17","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/jpet.116.234310","article-title":"Biliary elimination of pemetrexed is dependent on Mrp2 in rats: potential mechanism of variable response in nonalcoholic steatohepatitis","volume":"358","author":"Dzierlenga","year":"2016","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.dmd.2025.100043_bib18","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/clpt.2012.163","article-title":"Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1","volume":"92","author":"Elsby","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100043_bib19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1086-5802(16)31229-3","article-title":"Drug-related morbidity and mortality: updating the cost-of-illness model","volume":"41","author":"Ernst","year":"2001","journal-title":"J\u00a0Am Pharm Assoc (Wash)"},{"key":"10.1016\/j.dmd.2025.100043_bib20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejphar.2009.04.002","article-title":"Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats","volume":"613","author":"Fisher","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.dmd.2025.100043_bib21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications","volume":"65","author":"Francque","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.dmd.2025.100043_bib22","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2174\/138920012803341302","article-title":"Drug disposition in pathophysiological conditions","volume":"13","author":"Gandhi","year":"2012","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.dmd.2025.100043_bib23","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/00498254.2017.1295171","article-title":"Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition","volume":"48","author":"Hanna","year":"2018","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmd.2025.100043_bib24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/toxsci\/kfu156","article-title":"Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis","volume":"142","author":"Hardwick","year":"2014","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.dmd.2025.100043_bib25","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1124\/dmd.111.041012","article-title":"Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease","volume":"39","author":"Hardwick","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100043_bib26","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/dmd.111.041095","article-title":"Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis","volume":"40","author":"Hardwick","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100043_bib27","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/FPC.0b013e3280ef698f","article-title":"Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants","volume":"17","author":"Ho","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.dmd.2025.100043_bib28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.clpt.2006.01.010","article-title":"Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin","volume":"79","author":"Igel","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100043_bib29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2125.1999.00981.x","article-title":"Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use","volume":"48","author":"Impicciatore","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100043_bib30","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1016\/j.apsb.2021.05.030","article-title":"Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity","volume":"11","author":"Jilek","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.dmd.2025.100043_bib31","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1097\/MJT.0b013e3181f28f84","article-title":"Valsartan-induced angioedema in a patient on angiotensin-converting enzyme inhibitor for years: case report and literature review","volume":"19","author":"Kalra","year":"2012","journal-title":"Am J Ther"},{"key":"10.1016\/j.dmd.2025.100043_bib32","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/01.fpc.0000170913.73780.5f","article-title":"Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1\u22175, SLCO1B1\u221715 and SLCO1B1\u221715+C1007G, by using transient expression systems of HeLa and HEK293 cells","volume":"15","author":"Kameyama","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.dmd.2025.100043_bib33","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.xphs.2020.06.016","article-title":"Assessing OATP1B1- and OATP1B3-mediated drug-drug interaction potential of vemurafenib using R-value and physiologically-based pharmacokinetic models","volume":"110","author":"Kayesh","year":"2021","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.dmd.2025.100043_bib34","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1345\/aph.1L037","article-title":"Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies","volume":"42","author":"Kongkaew","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.dmd.2025.100043_bib35","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1080\/17474124.2021.1991792","article-title":"Current epidemiology in hepatocellular carcinoma","volume":"15","author":"Konyn","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dmd.2025.100043_bib36","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","volume":"2014","author":"Li","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.dmd.2025.100043_bib37","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1124\/dmd.107.015107","article-title":"Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease","volume":"35","author":"Lickteig","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100043_bib38","article-title":"Multi-target approaches in metabolic syndrome","volume":"11","author":"Lillich","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.dmd.2025.100043_bib39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1248\/bpb.b14-00767","article-title":"Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs","volume":"38","author":"Maeda","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.dmd.2025.100043_bib40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1124\/dmd.118.084194","article-title":"Hepatic organic anion transporting polypeptide-mediated clearance in the beagle dog: assessing in\u00a0vitro-in\u00a0vivo relationships and applying cross-species empirical scaling factors to improve prediction of human clearance","volume":"47","author":"Matsunaga","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100043_bib41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/molpharm.120.000169","article-title":"Predicting drug interactions with human equilibrative nucleoside transporters 1 and 2 using functional knockout cell lines and bayesian modeling","volume":"99","author":"Miller","year":"2021","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.dmd.2025.100043_bib42","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2165\/00002018-200427130-00006","article-title":"The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients","volume":"27","author":"Neubert","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.dmd.2025.100043_bib43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.dmd.2025.100043_bib44","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1124\/dmd.104.001909","article-title":"Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in\u00a0vitro evidence and effect of single nucleotide polymorphisms","volume":"33","author":"Nozawa","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100043_bib45","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00228-006-0123-1","article-title":"Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population","volume":"62","author":"Pasanen","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100043_bib46","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/1574886311666160225150106","article-title":"Patterns of adverse drug reaction in the medical wards of a teaching hospital: a prospective observational cohort study","volume":"11","author":"Peter","year":"2016","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.dmd.2025.100043_bib47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.dmd.2025.100043_bib48","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1476-5381.2011.01724.x","article-title":"OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies","volume":"165","author":"Roth","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.dmd.2025.100043_bib49","article-title":"Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: a systematic review","volume":"41","author":"Sanyal","year":"2024","journal-title":"Am Heart J Plus"},{"key":"10.1016\/j.dmd.2025.100043_bib50","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dmd.2025.100043_bib51","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1124\/dmd.106.014407","article-title":"The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3","volume":"35","author":"Seithel","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100043_bib52","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dmd.2025.100043_bib53","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/FPC.0000000000000148","article-title":"SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid","volume":"25","author":"Tornio","year":"2015","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.dmd.2025.100043_bib54","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/1078-0432.CCR-12-2080","article-title":"Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice","volume":"19","author":"van de Steeg","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dmd.2025.100043_bib55","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","article-title":"Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction","volume":"64","author":"Verbeeck","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100043_bib56","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The SLCO1B1\u22175 genetic variant is associated with statin-induced side effects","volume":"54","author":"Voora","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.dmd.2025.100043_bib57","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/clpt.2012.57","article-title":"The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy","volume":"92","author":"Wilke","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100043_bib58","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1124\/dmd.105.008938","article-title":"Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans","volume":"34","author":"Yamashiro","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100043_bib59","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/TP.0000000000002484","article-title":"Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation","volume":"103","author":"Younossi","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.dmd.2025.100043_bib60","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.phrs.2018.10.017","article-title":"Genetic variability and population diversity of the human SLCO (OATP) transporter family","volume":"139","author":"Zhang","year":"2019","journal-title":"Pharmacol Res"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562509052X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562509052X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T16:17:04Z","timestamp":1746116224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562509052X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S009095562509052X"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100043","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alterations of valsartan pharmacokinetics in a rodent model of metabolic dysfunction\u2013associated steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100043"}}